EQRx (EQRX) Treasury Stock : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is EQRx Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. EQRx's treasury stock for the quarter that ended in Sep. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

EQRx Treasury Stock Historical Data

The historical data trend for EQRx's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQRx Treasury Stock Chart

EQRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Treasury Stock

EQRx Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial								-	-	-	-	-

EQRx Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

EQRx (EQRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EQRx Inc (NAS:EQRX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, Cambridge, MA, USA, 02139

Website

https://www.eqrx.com

EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.

Executives

Dina Ciarimboli	officer: General Counsel and Secretary	EQRX, INC., 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Clive Meanwell	director	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Andreessen Horowitz Lsv Fund I-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Bio Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Lsv Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-q, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Krishna Yeshwant	director	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Kathryn E Giusti	director	1499 POST ROAD, FAIRFIELD CT 06824
Melanie Nallicheri	director, officer: Chief Executive Officer	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Ah Bio Fund Iii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025